The global liquid biopsy market is projected to reach USD 2,047.9
Million by 2022 from USD 715.7 Million in 2017, at a CAGR of 23.4%.

Factors such as increasing prevalence of cancer, increasing preference
for noninvasive procedures, initiatives undertaken by government and
global health organizations, technological advancements to augment
market revenues, rising emphasis on personalized medicine in clinical
practice, and increased funding for liquid biopsy R&D are driving the
growth of the market.

The number of companies offering liquid biopsy devices is increasing,
globally. Major market players are focusing on strengthening their
product offerings, mergers and acquisitions, and geographic presence by
entering into contracts and agreements with other established players in
the market. For instance, in January 2017, Bio-Rad Laboratories, Inc.
(US) entered into a definitive agreement with RainDance Technologies,
Inc. (US) to acquire the latter. The acquisition will result in
Bio-Rad's expansion into next-generation sequencing applications.

The report analyzes the liquid biopsy market by product, circulating
biomarker, clinical application, application, end user, and region. On
the basis of product and service, the market is segmented into assay
kits, instruments, and services. The assay kits segment is expected to
account for the largest share of the global market in 2017. Factors such
as the increasing demand for liquid biopsy tests, increasing
applications of liquid biopsies, and the need for reliable and specific
assays are expected to drive the market in the coming years.